All In Biotech

Drug Trial Radar · NCT04590963

Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer

A Phase 3 Randomized, Double-blind, Multicenter, Global Study of Monalizumab or Placebo in Combination With Cetuximab in Participants With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With an Immune Checkpoint Inhibitor

Last checked: Nov 20, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 370 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

370

Actual

Start

Oct 2, 2020

Primary completion

May 11, 2022

Study completion Sep 24, 2026

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Innate Pharma
First posted
Oct 19, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, multicenter, global Phase 3 study to assess the efficacy and safety of monalizumab and cetuximab, compared to placebo and cetuximab, in Participants with recurrent or metastatic head and neck cancer

Conditions

  • Squamous Cell Carcinoma of the Head and Neck

Interventions

  • MonalizumabDrug

    Participants will receive IV infusion of monalizumab as stated in arm description.

  • CetuximabDrug

    Participants will receive IV infusion of cetuximab as stated in arm description.

  • PlaceboOther

    Participants will receive IV infusion of placebo as stated in arm description.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS) in Human Papillomavirus (HPV)-Unrelated Analysis SetTime frame: Baseline (-28 to -1) through 17.5 months (maximum observed duration)

Locations

127 sites in 23 countries. Site status is shown where the registry gives one.

  • Research Site

    Tucson, Arizona

  • Research Site

    Chicago, Illinois

  • Research Site

    Westwood, Kansas

  • Research Site

    Boston, Massachusetts

  • Research Site

    Ann Arbor, Michigan

  • Research Site

    Rochester, Minnesota

  • Research Site

    St Louis, Missouri

  • Research Site

    Las Vegas, Nevada

  • Research Site

    New York, New York

  • Research Site

    Charlotte, North Carolina

  • Research Site

    Winston-Salem, North Carolina

  • Research Site

    Columbus, Ohio

  • Research Site

    Philadelphia, Pennsylvania

  • Research Site

    Philadelphia, Pennsylvania

  • Research Site

    Pittsburgh, Pennsylvania

  • Research Site

    Dallas, Texas

  • Research Site

    Houston, Texas

  • Research Site

    CABA, Argentina

  • Research Site

    CABA, Argentina

  • Research Site

    CABA, Argentina

  • Research Site

    Camperdown, Australia

  • Research Site

    Elizabeth Vale, Australia

  • Research Site

    Heidelberg, Australia

  • Research Site

    Melbourne, Australia

  • Research Site

    Linz, Austria

  • Research Site

    Brussels, Belgium

  • Research Site

    Leuven, Belgium

  • Research Site

    Namur, Belgium

  • Research Site

    Roeselare, Belgium

  • Research Site

    Belo Horizonte, Brazil

  • Research Site

    Porto Alegre, Brazil

  • Research Site

    Rio de Janeiro, Brazil

  • Research Site

    São Paulo, Brazil

  • Research Site

    São Paulo, Brazil

  • Research Site

    São Paulo, Brazil

  • Research Site

    São Paulo, Brazil

  • Research Site

    Panagyurishte, Bulgaria

  • Research Site

    Plovdiv, Bulgaria

  • Research Site

    Sofia, Bulgaria

  • Research Site

    Victoria, British Columbia, Canada

Showing 40 of 127 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.